To meet growing demand from the pharmaceutical industry, Asahi Kasei has established Asahi Kasei Life Science to operate its bioprocess businesses under a new organizational structure.
Asahi Kasei announced that it will construct an integrated plant in Ontario, Canada for the base film manufacturing and coating of Hipore wet-process lithium-ion battery (LIB) separator. Asahi Kasei and Honda Motor Co., Ltd. (Honda) have reached a basic agreement about the plant and are currently exploring the possibility of a joint investment.
Japanese manufacturer Asahi Kasei invests in Canadian startup Ionomr Innovations, known for its high-performance anion exchange membrane (AEM). The membrane has applications in cost-efficient and scalable green hydrogen production.
Asahi Kasei will invest in new coating equipment for Hipore lithium-ion battery separators in its US, Japan, and South Korea facilities, starting in the first half of fiscal year 2026. The increased capacity will provide coated separators for batteries powering up to 1.7 million electric vehicles.
Japan-based multinational chemical producer Asahi Kasei has begun construction of an alkaline water electrolysis pilot test plant for hydrogen production in Kawasaki, Japan.
Asahi Kasei Medical, through a US subsidiary, has agreed to buy biologics CDMO Bionova Scientific for an undisclosed sum. Located in Fremont, California, Bionova provides process development services to biopharmaceutical companies, especially those developing next-generation antibody-based drugs.
The European Chemical Industry has set out on an ambitious path to become carbon neutral. Germany, as one of the major chemical manufacturing nations, has committed to achieve this goal by 2050.
As Managing Director of Asahi Kasei Europe, Hideki Tsutsumi has implemented the Japanese chemical company's growth strategy in Europe.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
